Khiron Life Sciences on Midas Letter

Khiron Life Sciences Corp. (TSXV:KHRN) has been recently featured in an article on on Midas Letter as the company proceeds to take a deeper plunge into the burgeoning medical cannabis market.

Earlier today, Khiron announced that it has been “registered by the Colombian Agricultural Institute (ICA) as an agronomical unit.” This is a huge triumph for the company as they are now able to begin commercial cultivation of high THC strains “requiring quota, and to cultivate and produce CBD strains not requiring quota.” The ICA authorization perfectly positions the company to become the premier cannabis company to bring cannabis products to the Columbian market.

The article outlines the large amount of red tape involved in securing the ICA registration, similar to the GMP-certification process in the European Union. Khiron’s ICA approval makes them only the second company to achieve this certification domestically.

“Ultimately, Khiron should get first crack to sell its medical products in the Colombian market. That market—at least by population—is about 37% larger than the Canadian market and contains a medical cannabis patient pool of roughly 5.6 million people. All told, there’s a potential of 100 million annual and re-occurring dollars up for grabs.”

To read the full article, click here.

Click here to connect with Khiron Life Sciences Corp. (TSXV:KHRN) for an Investor Presentation

The post Khiron Life Sciences on Midas Letter appeared first on Investing News Network.


Leave A Reply

Your email address will not be published.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

Accessibility Tools